Literature DB >> 25624992

Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Zhao-Shan Niu1, Xiao-Jun Niu1, Mei Wang1.   

Abstract

Hepatocellular carcinoma (HCC) accounts for over 90% of all primary liver cancers. With an ever increasing incidence trend year by year, it has become the third most common cause of death from cancer worldwide. Hepatic resection is generally considered to be one of the most effective therapies for HCC patients, however, there is a high risk of recurrence in postoperative HCC. In clinical practice, there exists an urgent need for valid prognostic markers to identify patients with prognosis, hence the importance of studies on prognostic markers in improving the prediction of HCC prognosis. This review focuses on the most promising immunohistochemical prognostic markers in predicting the postoperative survival of HCC patients.

Entities:  

Keywords:  Hepatocellular carcinoma; Immunohistochemical; Management; Predictive marker; Prognostic marker

Year:  2015        PMID: 25624992      PMCID: PMC4295195          DOI: 10.4254/wjh.v7.i1.7

Source DB:  PubMed          Journal:  World J Hepatol


  233 in total

1.  Immunohistochemical analysis of bone morphological protein signaling pathway in human myometrium.

Authors:  Caroline Rouleau; Caroline Rico; Ilona Hapkova; Pascal de Santa Barbara
Journal:  Exp Mol Pathol       Date:  2012-04-17       Impact factor: 3.362

2.  Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients.

Authors:  Su Ning; Chen Bin; Huang Na; Shen Peng; Ding Yi; Ye Xiang-hua; Zeng Fang-yin; Zheng Da-yong; Luo Rong-cheng
Journal:  Mol Biol Rep       Date:  2011-06-08       Impact factor: 2.316

Review 3.  The cancer biomarker osteopontin: combination with other markers.

Authors:  Georg F Weber
Journal:  Cancer Genomics Proteomics       Date:  2011 Nov-Dec       Impact factor: 4.069

4.  Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.

Authors:  Rong-Ping Guo; Chong Zhong; Ming Shi; Chang-Qing Zhang; Wei Wei; Ya-Qi Zhang; Jin-Qing Li
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-09       Impact factor: 4.553

5.  Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.

Authors:  Yoon Hee Lee; Jin-hyung Heo; Tae Heon Kim; Haeyoun Kang; Gwangil Kim; Jiyoung Kim; Sang-ho Cho; Hee Jung An
Journal:  Int J Gynecol Pathol       Date:  2011-05       Impact factor: 2.762

6.  Expression of E-cadherin and vascular endothelial growth factor in noncancerous liver is associated with recurrence of hepatocellular carcinoma after curative resection.

Authors:  Mutsuko Minata; Masatoshi Kudo; Kouji H Harada; Iwao Ikai; Naoshi Nishida
Journal:  Oncology       Date:  2013-02-20       Impact factor: 2.935

7.  The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure.

Authors:  Lu-Nan Qi; Tao Bai; Zu-Shun Chen; Fei-Xiang Wu; Yuan-Yuan Chen; Bang- De Xiang; Tao Peng; Ze-Guang Han; Le-Qun Li
Journal:  Liver Int       Date:  2014-01-27       Impact factor: 5.828

Review 8.  Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.

Authors:  Dong-Xing Cao; Zhi-Jie Li; Xiao-Ou Jiang; Yick Liang Lum; Ester Khin; Nikki P Lee; Guo-Hao Wu; John M Luk
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

9.  Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.

Authors:  Shun-Jun Fu; Chao-Ying Qi; Wei-Kai Xiao; Shao-Qiang Li; Bao-Gang Peng; Li-Jian Liang
Journal:  Surgery       Date:  2013-04-16       Impact factor: 3.982

10.  Clinicopathologic significance of the expression of Snail in hepatocellular carcinoma.

Authors:  Hyun Young Woo; Ae Lyoung Min; Jong Young Choi; Si Hyun Bae; Seung Kew Yoon; Chan Kwon Jung
Journal:  Korean J Hepatol       Date:  2011-03
View more
  6 in total

1.  SQSTM1 Expression in Hepatocellular Carcinoma and Relation to Tumor Recurrence After Radiofrequency Ablation.

Authors:  Amr Abdel-Moety; Nahed Baddour; Perihan Salem; Hesham El-Tobgy; Assem El-Shendidi
Journal:  J Clin Exp Hepatol       Date:  2021-12-09

2.  MR Features Based on LI-RADS Ver. 2018 Correlated with Cytokeratin 19 Expression in Combined Hepatocellular Carcinoma-Cholangiocarcinoma.

Authors:  Changwu Zhou; Xiaoyan Ni; Xin Lu; Yi Wang; Xianling Qian; Chun Yang; Mengsu Zeng
Journal:  J Hepatocell Carcinoma       Date:  2021-08-21

3.  Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases.

Authors:  Aloísio Felipe-Silva; Alda Wakamatsu; Cinthya Dos Santos Cirqueira; Venâncio Avancini Ferreira Alves
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

4.  Texture analysis on gadoxetic acid enhanced-MRI for predicting Ki-67 status in hepatocellular carcinoma: A prospective study.

Authors:  Zheng Ye; Hanyu Jiang; Jie Chen; Xijiao Liu; Yi Wei; Chunchao Xia; Ting Duan; Likun Cao; Zhen Zhang; Bin Song
Journal:  Chin J Cancer Res       Date:  2019-10       Impact factor: 5.087

5.  Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.

Authors:  Guangchao Cao; Xiaoyun Li; Chao Qin; Jie Li
Journal:  Med Sci Monit       Date:  2015-10-18

6.  Expression and clinical significance of miR-3615 in hepatocellular carcinoma.

Authors:  Xin Yuan; Yize Zhang; Zujiang Yu
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.